Jafron Biomedical Co.,Ltd. (SHE:300529)

Market Cap	17.04B
Revenue (ttm)	2.48B
Net Income (ttm)	724.21M
Shares Out	774.36M
EPS (ttm)	0.93
PE Ratio	23.73
Forward PE	16.75
Dividend	0.80 (3.67%)
Ex-Dividend Date	May 31, 2024

Volume	4,645,300
Average Volume	8,587,749
Open	21.92
Previous Close	22.11
Day's Range	21.89 - 22.22
52-Week Range	21.72 - 39.24
Beta	0.59
RSI	31.33
Earnings Date	Apr 16, 2025

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis co...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,797
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.